Valeant Pharmaceuticals International, Inc. (TSE:VRX) (NYSE:VRX) shares traded up 0.1% during trading on Friday . The company traded as high as C$29.30 and last traded at C$28.83. 1,648,424 shares traded hands during mid-day trading, a decline of 11% from the average session volume of 1,842,347 shares. The stock had previously closed at C$28.86.
A number of research analysts have commented on the company. Royal Bank of Canada lowered their target price on Valeant Pharmaceuticals International to C$22.50 and set a “sector perform” rating on the stock in a research note on Friday, October 20th. TD Securities upgraded Valeant Pharmaceuticals International from a “hold” rating to a “buy” rating and set a C$25.50 target price on the stock in a research note on Wednesday, November 8th.
The stock has a market cap of $10,370.00, a P/E ratio of 5.92 and a beta of -0.67.
In related news, Director Schutter Richard Urbain De purchased 10,000 shares of the firm’s stock in a transaction dated Friday, November 17th. The stock was bought at an average price of C$14.33 per share, for a total transaction of C$143,300.00.
TRADEMARK VIOLATION NOTICE: This article was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The correct version of this article can be read at https://www.dispatchtribunal.com/2018/01/05/valeant-pharmaceuticals-international-vrx-trading-0-1-higher.html.
Valeant Pharmaceuticals International Company Profile
Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).
Receive News & Ratings for Valeant Pharmaceuticals International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International and related companies with MarketBeat.com's FREE daily email newsletter.